Clinical trials: Moderate-to-severe Chronic Plaque Psoriasis
Psoriasis
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645814
- Testing
- adalimumab
- Volunteers
- 148 people
- Sponsor
- Abbott
Chronic Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with…
- Trial name
- BE ABLE 1 (NCT02905006)
- Testing
- Bimekizumab
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 250 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
- Trial name
- NCT04930042
- Testing
- Stelara, AVT04
- Where
- 30 sites in Estonia, Georgia and 2 more
- Volunteers
- 581 people
- Sponsor
- Alvotech Swiss AG
Moderate-to-severe Chronic Plaque Psoriasis
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
The purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in Spain.
- Trial name
- PROMISE (NCT01076192)
- Volunteers
- 547 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Chronic Stable Plaque Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
- Trial name
- EGALITY (NCT01891864)
- Testing
- GP2015 Etanercept, Enbrel
- Where
- 74 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 531 people
- Sponsor
- Sandoz
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis, Psoriasis
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT02581345
- Testing
- M923, Humira
- Where
- 90 sites in United States, Bulgaria and 7 more
- Volunteers
- 572 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Plaque Psoriasis
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
Assess the efficacy and safety of alefacept with nbUVB compared to alefacept alone in chronic plaque psoriasis subjects. Combination therapy may improve the clinical response to psoriatic subjects as both modalities have an…
- Trial name
- NCT00658606
- Testing
- alefacept, Narrow Band UVB Phototherapy
- Where
- 12 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Inc
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Psoriasis
Adalimumab in Adult Japanese Subjects With Psoriasis
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
- Trial name
- NCT00647400
- Testing
- adalimumab
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- Abbott
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
- Trial name
- Psoriasis (NCT06110676)
- Testing
- LZM012, Secukinumab
- Where
- China
- Volunteers
- 918 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Moderate to Severe Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00710580
- Testing
- ABT-874, etanercept
- Where
- 42 sites in United States
- Volunteers
- 350 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate to Severe Chronic Plaque Psoriasis
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug.
- Trial name
- NCT06591273
- Testing
- Infliximab-dyyb Biosimilar (Remsima)
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG
Chronic Plaque Psoriasis, Obesity
Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.
- Trial name
- NCT00512187
- Testing
- low calorie diet
- Where
- Italy
- Sponsor
- Universita di Verona